Aiping Bai to Enzyme Inhibitors
This is a "connection" page, showing publications Aiping Bai has written about Enzyme Inhibitors.
Connection Strength
1.136
-
Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites. Bioorg Med Chem. 2018 12 15; 26(23-24):6067-6075.
Score: 0.508
-
Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15; 22(24):6933-44.
Score: 0.384
-
Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. Oncotarget. 2016 Dec 20; 7(51):83907-83925.
Score: 0.112
-
Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem. 2009 Mar 01; 17(5):1840-8.
Score: 0.065
-
Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res. 2017 12 15; 77(24):6950-6962.
Score: 0.030
-
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
Score: 0.016
-
Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp Cell Res. 2004 Jan 15; 292(2):385-92.
Score: 0.011
-
Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages. Acta Pharmacol Sin. 2002 Aug; 23(8):762-8.
Score: 0.010